MacroGenics, Inc.
NASDAQ:MGNX
Overview | Financials
| Company Name | MacroGenics, Inc. |
| Symbol | MGNX |
| Currency | USD |
| Price | 1.76 |
| Market Cap | 111,242,032 |
| Dividend Yield | 0% |
| 52-week-range | 0.99 - 5.1 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Dr. Scott Koenig M.D., Ph.D. |
| Website | https://www.macrogenics.com |
An error occurred while fetching data.
About MacroGenics, Inc.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD








